肿瘤影像学中分子靶向治疗的胆道与胰腺并发症
本综述旨在让放射科医生熟悉分子靶向治疗胆道与胰腺毒性的不同影像表现。胆胰毒性表现多样、程度不一,可从无症状肝功酶升高到急性胰腺炎或胆囊炎,处理取决于临床情况和所见严重程度。文章介绍最常相关的药物类别、影像表现与鉴别诊断,并提供处理指南。
要点
- 分子靶向治疗可致胆道与胰腺毒性,表现从无症状肝功酶升高到急性胰腺炎或胆囊炎。
- 放射科医生需熟悉相关药物类别及其类特异性毒性,以识别胆胰系统损伤的影像表现。
- 药物相关胆胰损伤需与其它病因鉴别,处理取决于临床情况和影像所见严重程度。
核心结论
- 分子靶向治疗的胆道与胰腺毒性表现多样、程度不一,影像认识有助于鉴别诊断并指导处理。
研究设计与样本
- 综述,旨在让放射科医生熟悉分子靶向治疗胆道与胰腺毒性的影像表现。
临床应用与阅片要点
- 文章介绍最常与胆胰毒性相关的分子靶向治疗类别、药物相关胆胰损伤的影像表现及可能鉴别诊断,并提供这些情况的处理指南。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The purpose of this review is to familiarize radiologists with the different imaging manifestations of biliary and pancreatic toxicity of molecular targeted therapies. The advent of molecular targeted therapies for cancer treatment has prompted radiologists to be familiar with these new molecules, their patterns of response, and their class-specific toxicities. While liver and bowel toxicities have been extensively reported in literature, less is known about the pathogenesis and imaging of toxicity involving the pancreatobiliary system. Biliary and pancreatic toxicity of molecular targeted therapies present with variable manifestations and varying degrees of severity, from asymptomatic liver function tests elevation to acute pancreatitis or cholecystitis. Management of these conditions depends on the clinical scenario and the severity of the findings. In this article, we will (1) present the various classes of molecular targeted therapies most commonly associated with biliary and pancreatic toxicity; (2) illustrate imaging findings of drug-associated biliary and pancreatic injuries and their possible differential diagnosis; and (3) provide a guide for management of these conditions.
引用
- Alessandrino F, Krajewski KM, Tirumani SH, et al. Biliary and pancreatic complications of molecular targeted therapies in cancer imaging. Abdom Radiol (NY). 2017. PMID: 28160038. doi:10.1007/s00261-017-1050-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。